Database

Startups

Main Industry
Health Care
Main Product/Service
Kentec’s core business includes EMS (Electronics Manufacturing Services) — full-process manufacturing and turnkey services covering SMT, DIP, system assembly, testing, packaging and material-kitting for products ranging from industrial PCs, networking equ
Founded Year
2025
Unified Business No.
60543799
Status
Active
Number of Employees
10
Total Paid-in Capital
21,130,000 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
Kentec Inc. is a professional electronics-manufacturing service provider founded in 2010, offering turnkey services — including OEM/ODM/JDM, SMT & DIP, full product assembly, testing and packaging — for a wide range of electronic products such as industri



More ↓

Similar Companies

EPISONICA CORPORATION

ArcBlate 100M is a MR-guided High Intensity Focused Ultrasound(MRgHIFU) designed to be use with magnetic resonance imaging (MRI) system. Using the MRgHIFU to perform a non-invasive procedure through a top-mounted transducer for soft tissue ablation in the

Garage Brain Science Co., Ltd.

The company’s product pipeline is built upon its proprietary research published in high-impact journals like Nature Communications, targeting protein dysregulation associated with conditions such as Motor Neuron Disease (MND), Alzheimer’s disease, and Parkinson’s disease. GBS focuses on developing precision drug candidates that address the underlying mechanisms of prion-like protein aggregation, aiming to provide effective treatments for complex neurological disorders that currently lack successful therapeutic options.